From a therapeutic perspective, we have identified uPAR as a promising target for peptide receptor radionuclide therapy (PRRT) and our team has previously demonstrated the therapeutic efficacy of uPAR-targeted PRRT in preclinical models of prostate and colorectal cancers [20, 21]. Here, PLAUR is linked to colorectal cancer.